davelovescoconuts

Does maps have any plans to do a true drug discovery campaign into any analogs of “classic” psychoactive compounds for increased potency/selectivity? Or is that something left to other groups to pursue and your focus is on existing compounds?

Was this decision made because the enantiomers showed no difference in potency or due to financial constraints of the med chem/development to explore enantiomers?

Completely understand the need to stick with racemate since you began with that data and dont want to start over and redo it all.

Once approved by the FDA will there be development of optimized ratios other than 50/50 to benefits or will MAPS consider the MDMA drug approval project closed/not worth the time/effort/money to go back through additional trials for potentially negligible difference? Just curious what the nonprofit view is on it since it's obviously helping people quite a bit and will be a known therapeutic drug at that point. Is there potential for it to perform better or is that money better spent on other projects?